Published on 30 Nov 2021 on Zacks via Yahoo Finance
DaVita (DVA) Study Favors mRNA Vaccines for Dialysis Patients
DaVita Inc. DVA recently announced that its DaVita Clinical Research (“DCR”) study has found that dialysis patients who received mRNA COVID-19 vaccines were at a lower risk of contracting the COVID-19 infection post-vaccination. The study also found that vaccinated patients were less likely to be hospitalized or die following breakthrough infection, unlike the unvaccinated patients.
The DCR study result was published online ahead of print by the Journal of the American Society of Nephrology.
The favorable study outcome regarding vaccination of patients suffering from end-stage kidney disease (“ESKD”) is expected to be a major achievement for DaVita.